Tag Archives: Salix Pharmaceuticals

Santarus (NASDAQ:SNTS) Stock Hikes as Profit Outshines Forecasts

Posted on March 5, 2013 by Thomas Vedder

Santarus, Inc (NASDAQ:SNTS) stock surged 11% in afterhours trading session on Monday after the San Diego, California based company announced better-than-forecasted results for the fiscal Q4 and also estimate earnings for fiscal 2013 more than analysts’ forecasts.

The company announced …

Posted in Healthcare, Main Post | Tagged GlaxoSmithKline, GSK, Merck, MRK, NASDAQ:SLXP, NASDAQ:SNTS, NYSE:GSK, NYSE:MRK, Salix Pharmaceuticals, Santarus, SLXP, SNTS | Comments Off

Salix Pharmaceuticals Ltd.’s (NASDAQ:SLXP) Gets FDA Approval for Fulyzaq – SLXP, GSK, WCRX, PFE, MRK, HLF, ABT, VVUS, WPI

Posted on January 2, 2013 by Thomas Vedder

The Food and Drug Administration has accepted the initial anti-diarrheal drug for HIV/AIDS patients, Salix Pharmaceuticals Ltd.’s (NASDAQ:SLXP) Fulyzaq.

The medicine, also called as crofelemer, is created to get rid of symptoms of noninfectious diarrhea in patients with HIV/AIDS on …

Posted in Healthcare, Latest Headlines | Tagged Abbott, ABT, GlaxoSmithKline, GSK, Herbalife, HLF, Merck, MRK, NASDAQ:SLXP, NASDAQ:VVUS, NASDAQ:WCRX, NYSE:ABT, NYSE:GSK, NYSE:HLF, NYSE:MRK, NYSE:PFE, NYSE:WPI, PFE, Pfizer, Salix Pharmaceuticals, SLXP, Vivus, VVUS, Warner Chilcott, Watson, WCRX, WPI | Comments Off

At the bell market buzz (SLXP, BZH, BAX)

Posted on December 20, 2011 by Cameron White

In this report: Salix Pharmaceuticals (NASDAQ:SLXP), Beazer Homes USA (NYSE:BZH) and Baxter International (NYSE:BAX).

Salix Pharmaceuticals (NASDAQ:SLXP) shares jumped over 9 percent higher today after the company reported positive phase-3 data for its Relistor drug which treats constipation in patients …

Posted in Latest Headlines, Reports | Tagged acquired, Analysts, BAX, Baxter International, Beazer Homes USA, BZH, Commerce Department, company, deal, downgrade, economists, firm, housing, HOV, Hovnanian Enterprises, KB Homes, KBH, marketing, milestones, NASDAQ, NASDAQ:SLXP, NYSE, NYSE:BAX, NYSE:BZH, NYSE:HOV, NYSE:KBH, patients, Phase 3, Progenics Pharmaceuticals, rating, RBC Capital, relistor, sales, Salix Pharmaceuticals, share, shares, SLXP, stock, top pick | Comments Off

Big time losers and the reasons why (CADX, SLXP, QEP)

Posted on November 14, 2011 by Martin Timble

In this report: QEP Resources (NYSE:QEP), Salix Pharmaceuticals (NASDAQ:SLXP) and Cadence Pharmaceuticals (NASDAQ:CADX).

QEP Resources (NYSE:QEP) has dropped by more than 6 percent today after the company said that it expects 2012 organic production growth of 12 to 14 percent, …

Posted in Latest Headlines, Reports | Tagged adjusted, Analysts, approval, biopharmaceutical, Cadence Pharmaceuticals, CADX, company, development, dilution, earnings, estimate, expects, Food and Drug Administration, market, meeting, NASDAQ, NASDAQ:CADX, NASDAQ:SLXP, NYSE, NYSE:QEP, positions, production growth, public stock, QEP, QEP Resources, regulators, Salix Pharmaceuticals, sell, shareholders, SLXP, sold off, stock offering, treatment, Xifaxan | Comments Off

What the fuss Adobe Systems, Morgan Stanley and Salix Pharmaceuticals?

Posted on November 9, 2011 by Josie Middleton

In this report: Adobe Systems (NASDAQ:ADBE), Morgan Stanley (NYSE:MS) and Salix Pharmaceuticals (NASDAQ:SLXP).

Adobe Systems (NASDAQ:ADBE) dropped more than 7 percent today after the company announced that it would cut 750 jobs as it put an end to its Flash …

Posted in Latest Headlines, Reports | Tagged Adam Myers, ADBE, Adobe Systems, advertising, analyst, company, concerns, costs, crisis, digital, earned, earnings, Europe, expectations, flash technology, government, Italy, mobile device, Morgan Stanley, MS, NASDAQ, NASDAQ:ADBE, NASDAQ:SLXP, NYSE, NYSE:MS, Oceana Therapeutics, Prime Minister, products, profit, publishing, quarter, Salix Pharmaceuticals, SLXP, software, tablet | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.